Allegations Of EU Notified Body Fees Having Escalated And Of Being Unpredictable
US medtech companies are worried EU notified bodies have too much freedom over setting their fees, accusing them of lacking transparency and being inconsistent with what they charge. They also allege that notified body practices mean some products will miss the four-year grace period.
You may also be interested in...
While the EU has selected the CND system as the basis for its nomenclature, GMDN is becoming increasingly valued on the US and international scene. How does it see its latest role panning out globally?
Updated medtech notified body figures from the European Commission always make headline news. But industry needs to see real appointments now, not a list of tricky-to-understand numbers.
Erik Hansson remains deputy head of devices in a move to the European Commission’s DG Sante from DG Grow. He now answers to a newly appointed devices head who shares a common educational background but whose recent pharmaceutical role may unsettle the devices industry.